Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

David Claxton, Harry P. Erba, Stefan Faderl, Martha Arellano, Roger M. Lyons, Tibor Kovacsovics, Janice Gabrilove, Dirk Huebner, Pritesh J. Gandhi, Hagop Kantarjian

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This report describes outpatient (OP) administration of clofarabine in older patients (≥60 years) with untreated acute myelogenous leukemia (AML). Overall, 112 patients underwent clofarabine induction. Clofarabine was administered to 35 OPs for a total of 72 OP cycles, with 81% of these cycles representing consolidation treatment. Median length of hospital stay was 06 days and 525 days across OP and inpatient (IP) cycles, respectively. The most common adverse events (AEs) were nausea, vomiting, diarrhea, febrile neutropenia, edema, hypokalemia and pneumonia. The overall frequency of treatment-emergent grade ≥3 AEs and serious AEs was generally not different with IP or OP administration of clofarabine. No deaths were reported within 30 days following OP or IP consolidation cycles. In the appropriately selected older patient, OP administration of clofarabine consolidation appears feasible, is as well tolerated as IP administration and has potential to contribute to the quality of life in elderly patients with AML.

Original languageEnglish (US)
Pages (from-to)435-440
Number of pages6
JournalLeukemia and Lymphoma
Volume53
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Acute Myeloid Leukemia
Outpatients
Inpatients
Length of Stay
Therapeutics
Febrile Neutropenia
Hypokalemia
Nausea
Vomiting
clofarabine
Diarrhea
Edema
Pneumonia
Quality of Life

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Claxton, David ; Erba, Harry P. ; Faderl, Stefan ; Arellano, Martha ; Lyons, Roger M. ; Kovacsovics, Tibor ; Gabrilove, Janice ; Huebner, Dirk ; Gandhi, Pritesh J. ; Kantarjian, Hagop. / Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. In: Leukemia and Lymphoma. 2012 ; Vol. 53, No. 3. pp. 435-440.
@article{4fc556483ed34687a46b142c206c0d5a,
title = "Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia",
abstract = "This report describes outpatient (OP) administration of clofarabine in older patients (≥60 years) with untreated acute myelogenous leukemia (AML). Overall, 112 patients underwent clofarabine induction. Clofarabine was administered to 35 OPs for a total of 72 OP cycles, with 81{\%} of these cycles representing consolidation treatment. Median length of hospital stay was 06 days and 525 days across OP and inpatient (IP) cycles, respectively. The most common adverse events (AEs) were nausea, vomiting, diarrhea, febrile neutropenia, edema, hypokalemia and pneumonia. The overall frequency of treatment-emergent grade ≥3 AEs and serious AEs was generally not different with IP or OP administration of clofarabine. No deaths were reported within 30 days following OP or IP consolidation cycles. In the appropriately selected older patient, OP administration of clofarabine consolidation appears feasible, is as well tolerated as IP administration and has potential to contribute to the quality of life in elderly patients with AML.",
author = "David Claxton and Erba, {Harry P.} and Stefan Faderl and Martha Arellano and Lyons, {Roger M.} and Tibor Kovacsovics and Janice Gabrilove and Dirk Huebner and Gandhi, {Pritesh J.} and Hagop Kantarjian",
year = "2012",
month = "3",
day = "1",
doi = "10.3109/10428194.2011.616960",
language = "English (US)",
volume = "53",
pages = "435--440",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

Claxton, D, Erba, HP, Faderl, S, Arellano, M, Lyons, RM, Kovacsovics, T, Gabrilove, J, Huebner, D, Gandhi, PJ & Kantarjian, H 2012, 'Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia', Leukemia and Lymphoma, vol. 53, no. 3, pp. 435-440. https://doi.org/10.3109/10428194.2011.616960

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. / Claxton, David; Erba, Harry P.; Faderl, Stefan; Arellano, Martha; Lyons, Roger M.; Kovacsovics, Tibor; Gabrilove, Janice; Huebner, Dirk; Gandhi, Pritesh J.; Kantarjian, Hagop.

In: Leukemia and Lymphoma, Vol. 53, No. 3, 01.03.2012, p. 435-440.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

AU - Claxton, David

AU - Erba, Harry P.

AU - Faderl, Stefan

AU - Arellano, Martha

AU - Lyons, Roger M.

AU - Kovacsovics, Tibor

AU - Gabrilove, Janice

AU - Huebner, Dirk

AU - Gandhi, Pritesh J.

AU - Kantarjian, Hagop

PY - 2012/3/1

Y1 - 2012/3/1

N2 - This report describes outpatient (OP) administration of clofarabine in older patients (≥60 years) with untreated acute myelogenous leukemia (AML). Overall, 112 patients underwent clofarabine induction. Clofarabine was administered to 35 OPs for a total of 72 OP cycles, with 81% of these cycles representing consolidation treatment. Median length of hospital stay was 06 days and 525 days across OP and inpatient (IP) cycles, respectively. The most common adverse events (AEs) were nausea, vomiting, diarrhea, febrile neutropenia, edema, hypokalemia and pneumonia. The overall frequency of treatment-emergent grade ≥3 AEs and serious AEs was generally not different with IP or OP administration of clofarabine. No deaths were reported within 30 days following OP or IP consolidation cycles. In the appropriately selected older patient, OP administration of clofarabine consolidation appears feasible, is as well tolerated as IP administration and has potential to contribute to the quality of life in elderly patients with AML.

AB - This report describes outpatient (OP) administration of clofarabine in older patients (≥60 years) with untreated acute myelogenous leukemia (AML). Overall, 112 patients underwent clofarabine induction. Clofarabine was administered to 35 OPs for a total of 72 OP cycles, with 81% of these cycles representing consolidation treatment. Median length of hospital stay was 06 days and 525 days across OP and inpatient (IP) cycles, respectively. The most common adverse events (AEs) were nausea, vomiting, diarrhea, febrile neutropenia, edema, hypokalemia and pneumonia. The overall frequency of treatment-emergent grade ≥3 AEs and serious AEs was generally not different with IP or OP administration of clofarabine. No deaths were reported within 30 days following OP or IP consolidation cycles. In the appropriately selected older patient, OP administration of clofarabine consolidation appears feasible, is as well tolerated as IP administration and has potential to contribute to the quality of life in elderly patients with AML.

UR - http://www.scopus.com/inward/record.url?scp=84857531543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857531543&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.616960

DO - 10.3109/10428194.2011.616960

M3 - Article

C2 - 21877883

AN - SCOPUS:84857531543

VL - 53

SP - 435

EP - 440

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -